Tabelecleucel
Ebvallo (tabelecleucel) is a cell pharmaceutical. Tabelecleucel was first approved as Ebvallo on 2022-12-16. It has been approved in Europe to treat lymphoproliferative disorders.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
77 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epstein-barr virus infections | D020031 | EFO_0000769 | — | 20 | 13 | 2 | — | 4 | 34 |
| Infections | D007239 | EFO_0000544 | — | 11 | 5 | 1 | — | 3 | 16 |
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 10 | 5 | 1 | — | 1 | 15 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 10 | 4 | 1 | — | 1 | 14 |
| Nasopharyngeal neoplasms | D009303 | — | — | 9 | 4 | 1 | — | 1 | 13 |
| Communicable diseases | D003141 | — | — | 8 | 4 | 1 | — | 3 | 13 |
| Virus diseases | D014777 | — | B34 | 7 | 3 | 1 | — | 3 | 11 |
| Adenoviridae infections | D000257 | EFO_1001259 | B34.0 | 7 | 3 | 1 | — | 2 | 10 |
| Carcinoma | D002277 | — | C80.0 | 6 | 3 | 1 | — | — | 8 |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | 4 | 2 | 1 | — | 2 | 7 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 22 | 11 | — | — | 1 | 29 |
| Hodgkin disease | D006689 | — | C81 | 12 | 3 | — | — | — | 14 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 13 | 1 | — | — | — | 13 |
| Neoplasms | D009369 | — | C80 | 4 | 5 | — | — | — | 6 |
| Leukemia | D007938 | — | C95 | 5 | 3 | — | — | — | 6 |
| Leiomyosarcoma | D007890 | — | — | 3 | 1 | — | — | 1 | 5 |
| Viremia | D014766 | — | B34.9 | 2 | 3 | — | — | 1 | 4 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 4 | 2 | — | — | — | 4 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | — | 2 | — | — | 1 | 3 |
| Primary immunodeficiency diseases | D000081207 | — | — | — | 2 | — | — | 1 | 3 |
Show 24 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenoviridae | D000256 | — | — | 2 | — | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
| Smooth muscle tumor | D018235 | — | — | 1 | — | — | — | — | 1 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
| Aids-related lymphoma | D016483 | EFO_1001365 | — | — | — | — | — | 1 | 1 |
| Hemophagocytic lymphohistiocytosis | D051359 | — | D76.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tabelecleucel |
| INN | tabelecleucel |
| Description | Tabelecleucel, sold under the brand name Ebvallo, is a medication used for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Tabelecleucel is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in a human leukocyte antigen (HLA)-restricted manner. It is made of cells of the immune system called T-cells that have been taken from the recipient (allogeneic) and are then mixed with EBV-infected B-cells from the same donor.
|
| Classification | Cell |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3990008 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB17072 |
| UNII ID | G3NJ7M8N4H (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 101 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use